Doctors point to an increase in psychological health problems and psychiatric illnesses such as depression and anxiety related to the Sars-CoV-2 pandemic. Initial studies document this development, which experts believe may further intensify after the pandemic has subsided.
Psychopharmaceuticals are an important component of the therapy of mental illnesses. Many weeks and months often pass before the right medication and the appropriate dose have been determined for a patient.
What many do not know: Antidepressants in particular contain active substances, the effects of which are influenced by variants in genes, which can delay or even prevent successful therapy. With pharmacogenetic tests, it is possible to individually check whether and which variants a person has. With this knowledge, the doctor can adapt the active ingredient or the dosage to the personal genetic situation. The GIMS.pharma software system from bio.logis can be used to provide the wealth of information required for clinical use.